NEW YORK, June 2, 2025 /PRNewswire/ -- Ichnos Glenmark Innovation (IGI), a global, fully integrated clinical-stage biotechnology company focused on developing multispecifics™ in oncology, today ...

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Ichnos Glenmark Innovation (IGI), a global, fully integrated clinical-stage biotechnology company focused on developing multispecificsTM in oncology, today ...

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Ichnos Glenmark Innovation (IGI), a global, fully integrated clinical-stage biotechnology company focused on developing multispecifics TM in oncology, today ...

NEW YORK, June 2, 2025 /PRNewswire/ -- Ichnos Glenmark Innovation (IGI), a global, fully integrated clinical-stage biotechnology company focused on developing multispecificsTM in oncology, today ...

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Ichnos Glenmark Innovation (IGI), a global, fully integrated clinical-stage biotechnology company focused on developing multispecifics TM in oncology, today ...

- ISB 2001 is a first-in-class T cell-engaging (TCE) trispecific antibody based on Ichnos' proprietary BEAT ® platform that targets BCMA and CD38 on multiple myeloma (MM) cells. - ISB 2001 exhibited ...

No dose-limiting toxicities were observed up to weekly subcutaneous doses of 1.2 mg/kg, with mostly mild Cytokine Release Syndrome, no cases of neurotoxicity, and no discontinuations due to adverse ...

Article highlights preclinical findings demonstrating ISB 2001 can potentially overcome myeloma cell escape mechanisms to evade therapeutic anti-tumor activity Data show superior killing potency of ...

Glenmark stock surged over 10 per cent, hitting a fresh 52‑week high at Rs 1,905 following its biggest-ever licensing ...